Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr

Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.

Key figures
Value₹30.30 Cr
Source

NSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Dr. Lal Pathlabs Ltd: key numbers

Share price
₹1,915.70
Market cap
₹32,155 Cr
Revenue (annual)
₹2,763 Cr
Net profit (annual)
₹504.8 Cr
P/E (TTM)
59.3×Sector 51.1×
Promoter holding
52.93%-0.26% QoQ
FII holding
18.73%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Dr. Lal Pathlabs Ltd

All →

Other acquisition announcements

All →